Novartis AG

Child Organization: Novartis Corp

Novartis International AG is a multinational pharmaceutical company based in Basel, Switzerland, ranking number three in sales among the world-wide industry.[when?] Company sales totalled 36.173 billon US$ in 2008. Currently,[when?] Novartis is the sixth largest pharmaceutical company in terms of revenue ($41.5 billion in 2009) with a profit margin of about 20%, which is the same as its industry competitors. Novartis profits were down by 31% from 2007 levels. Novartis manufactures such drugs as clozapine (Clozaril), diclofenac (Voltaren), carbamazepine (Tegretol), valsartan (Diovan), imatinib mesylate and (Gleevec / Glivec). Additional agents include ciclosporin (Neoral / Sandimmun), letrozole (Femara), methylphenidate (Ritalin), terbinafine (Lamisil), and others. Renamed to Novartis following an acquisition by Ciba-Geigy, it owns Sandoz, a large manufacturer of generic drugs. The company formerly owned the Gerber Products Company, a major infant and baby products producer, but sold it to Nestlé on 1 September 2007.

Source: Wikipedia

Campaign Finance

Information

Figures are based on itemized contributions reported to the Federal Election Commission and state agencies. Please note that:

  • contributions under $200 are not reported, and so are not included in totals.
  • only contributions from individuals and organizations to candidates are included. Various accounting measures and more exotic contribution types are excluded.
  • contributions are matched based on organization and recipient name reported within each election cycle. Contributions using an incorrect or non-standard version of the name may be missed.
  • corporate name changes and mergers may cause figures to differ from those of the Center for Responsive Politics.
  • organization totals include known subsidiaries of the organization.

For more information, please see our campaign finance methodology page. Lobbyist bundling data is described on our lobbyist bundling methodology page.

Latest FEC Data

covers through committee's May 31, 2012 filing.
  • Summary

    overview of the committee's finances
    Total Raised:
    $511,446
    Total Spent:
    $534,474
    Cash on Hand:
    $110,299
    Debts:
    $0

Standardized Donation Information

covers through 2011. may lag behind FEC section above, as donors and industries are identified by hand.
  • Top Recipients

    Employee Color Block
    Individuals
    PAC Color Block
    PAC
    Includes contributions from the organization’s employees, their family members, and its political action committee.
  • Republicans vs. Democrats

    in dollars
  • State vs. Federal

    in dollars
  • Top PAC Recipients

    Employee Color Block
    Individuals
    PAC Color Block
    PAC
    Includes contributions from the organization’s employees, their family members, and its political action committee.
View all campaign finance data for Novartis AG Sources: OpenSecrets.org FollowTheMoney.org

Lobbying

$6,809,948 Spent
Information

Figures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.

For more information, please see our lobbying methodology page.

covers through Q3, 2011

Lobbying On Behalf of Novartis AG

View all lobbying data for Novartis AG Sources: OpenSecrets.org

Regulations

24 Mentions; 5 Submissions
Information

All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.

Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.

Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.

Regulations and public comments can be downloaded in bulk here.

updated from Regulations.gov on September 27, 2011

The tables show occurrences of "Novartis AG" in public comments on proposed federal regulations.

  • Documents Submitted by the Organization
    • Submissions
    • Agency
    • Docket
    • Date
    • Toggle 1 FDA Draft Guidance for Industry on Clinical Pharmacogenomics: Premarketing Evaluation in Early Phase Clinical Studies; Availability 2011
    • Toggle 1 FDA Disqualification of a Clinical Investigator 2011
    • Toggle 1 FDA Draft Guidance for Industry on Size of Beads in Drug Products Labeled for Sprinkle; Availability 2011
    • Toggle 1 FDA Patent Term Extension Application for GILENYA® (fingolimod), U.S. Patent No. 5,604,229 2011
    • Toggle 1 FDA Patent Term Extension Application for ONSIOR® (robenacoxib), U.S. Patent No. 7,115,662 2011
  • Mentions in Document Text
    • Mentions
    • Agency
    • Docket
    • Date
    • Toggle 4 FDA Advisory Committee, Workshops, and Conferences Notices Various Meeting Notices (eg., Task Force Meeting, etc.) 2011
    • Toggle 3 FDA Patent Term Extension Application for GILENYA® (fingolimod), U.S. Patent No. 5,604,229 2011
    • Toggle 1 FTC Granting of Early Termination of Waiting Period Under Premerger Notification Rules 2011
    • Toggle 1 FTC Granting of Request for Early Termination of Waiting Period under Premerger Notification Rules 2011
    • Toggle 1 CMS CMS-64 (Quarterly Medicaid Statement of Expenditures for the Medical Assistance Program) 2011
    • Toggle 1 PHMSA Council on Safe Transportation of Hazardous Articles, Inc. 2011
    • Toggle 1 FDA Determine whether Chloramphenicol Capsules 250 mg was withdrawn from sale for reasons other than safety or effectiveness and grant permission to relist application number A060851 2011
    • Toggle 1 FDA Draft Guidance for Industry on Clinical Pharmacogenomics: Premarketing Evaluation in Early Phase Clinical Studies; Availability 2011
    • Toggle 1 FDA Preventive Controls for Registered Human Food and Animal Food/Feed Facilities; Request for Comments 2011
    • Toggle 1 FTC Early Terminations of Waiting Periods under Premerger Notification Rules 2011

Contractor Misconduct

2 Instances
Information

This information is collected by the Project On Government Oversight from press releases, court documents, news reports and other public records. It is not meant to be an exhaustive account of all instances of federal contractor misconduct.

More information on each instance, including primary source documents, is available on POGO's site by clicking on the instance description. More information on POGO's methodology is available here.

covers through POGO's March 3, 2012 release
Misconduct Type Hired By Incident Year Disposition Penalty
Labor None Nationwide Wage and Hour Class Action Lawsuit 2012 Settlement $99,170,000
Antitrust None Pharmaceutical Industry Average Wholesale Price Litigation 2011 Settlement $0
View all contractor misconduct data for Novartis AG Sources: Federal Contractor Misconduct Database from POGO